Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study

T. R. Pedersen, K. Berg, T. J. Cook, O. Faergeman, T. Haghfelt, J. Kjekshus, T. Miettinen, T. A. Musliner, A. G. Olsson, K. Pyorala, G. Thorgeirsson, J. A. Tobert, H. Wedel and L. Wilhelmsen
University of Oslo, Norway.

BACKGROUND: Long-term safety is an important consideration in the selection and use of drugs, such as lipid-lowering agents, that are prescribed to reduce the risk of clinical events during long periods. METHODS: The Scandinavian Simvastatin Survival Study was designed to evaluate the effects of cholesterol lowering with simvastatin on mortality and morbidity in patients with coronary heart disease. The 4444 patients aged 35 to 70 years (mean, 58.9 years) with angina pectoris or previous myocardial infarction and serum cholesterol levels of 5.5 to 8.0 mmol/L (213-310 mg/dL) receiving a lipid-lowering diet were randomly assigned to take double-blind treatment with simvastatin, 20 to 40 mg once daily, or placebo. In addition to previously reported end-point events, detailed clinical and laboratory safety data were collected during a median follow-up period of 5.4 years (range in survivors, 4.9-6.2 years). RESULTS: The only clearly drug-related serious adverse event during the 5.4-year median follow-up period was a single reversible case of myopathy. The frequencies of persistent elevations of hepatic aminotransferase levels above 3 times the upper limit of normal and of nonviral hepatitis in the simvastatin and placebo treatment groups were not significantly different. Examination of the lens showed no between-group differences, and no previously unrecognized adverse effects of the drug were observed. There were no significant between-group differences in adverse events in any body system. In particular, the frequency of adverse events related to the central nervous system was similar in both groups. CONCLUSION: The safety profile of simvastatin, 20 to 40 mg daily, over 5 years was excellent.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Simvastatin Protects against Amyloid {beta} and HIV-1 Tat-Induced Promoter Activities of Inflammatory Genes in Brain Endothelial Cells
Andras et al.
Mol. Pharmacol. 2008;73:1424-1433.
ABSTRACT | FULL TEXT  

Survivin Down-regulation Plays a Crucial Role in 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase Inhibitor-induced Apoptosis in Cancer
Kaneko et al.
J. Biol. Chem. 2007;282:19273-19281.
ABSTRACT | FULL TEXT  

Statin Use and Risk of Colorectal Cancer
Coogan et al.
JNCI J Natl Cancer Inst 2007;99:32-40.
ABSTRACT | FULL TEXT  

Predictors of patients' preferences for treatments to prevent heart disease
Marshall et al.
Heart 2006;92:1651-1655.
ABSTRACT | FULL TEXT  

Chemoprevention of Familial Adenomatous Polyposis by Low Doses of Atorvastatin and Celecoxib Given Individually and in Combination to APCMin Mice.
Swamy et al.
Cancer Res. 2006;66:7370-7377.
ABSTRACT | FULL TEXT  

Stats on Statins: Anything but Static
McLaughlin
JNCI J Natl Cancer Inst 2006;98:4-5.
FULL TEXT  

Cholesterol-Lowering Drugs and Colorectal Cancer Incidence in a Large United States Cohort
Jacobs et al.
JNCI J Natl Cancer Inst 2006;98:69-72.
ABSTRACT | FULL TEXT  

The Role of Statins in Cancer Therapy.
Hindler et al.
The Oncologist 2006;11:306-315.
ABSTRACT | FULL TEXT  

The statin studies: from targeting hypercholesterolaemia to targeting the high-risk patient
Ong
QJM 2005;98:599-614.
ABSTRACT | FULL TEXT  

Simvastatin Treatment of Pulmonary Hypertension: An Observational Case Series
Kao
Chest 2005;127:1446-1452.
ABSTRACT | FULL TEXT  

Lovastatin inhibits tumor growth and lung metastasis in mouse mammary carcinoma model: a p53-independent mitochondrial-mediated apoptotic mechanism
Shibata et al.
Carcinogenesis 2004;25:1887-1898.
ABSTRACT | FULL TEXT  

Simvastatin Does Not Have a Clinically Significant Pharmacokinetic Interaction With Fenofibrate in Humans
Bergman et al.
J Clin Pharmacol 2004;44:1054-1062.
ABSTRACT | FULL TEXT  

Comparison of two methods of presenting risk information to patients about the side effects of medicines
Knapp et al.
Qual Saf Health Care 2004;13:176-180.
ABSTRACT | FULL TEXT  

Drug Treatment of Hyperlipidemia in Women
Walsh and Pignone
JAMA 2004;291:2243-2252.
ABSTRACT | FULL TEXT  

Lipid-Lowering Drugs and the Risk of Depression and Suicidal Behavior
Yang et al.
Arch Intern Med 2003;163:1926-1932.
ABSTRACT | FULL TEXT  

Cataract and the use of statins: a case-control study
Smeeth et al.
QJM 2003;96:337-343.
ABSTRACT | FULL TEXT  

Screening for Statin-Related Toxicity: The Yield of Transaminase and Creatine Kinase Measurements in a Primary Care Setting
Smith et al.
Arch Intern Med 2003;163:688-692.
ABSTRACT | FULL TEXT  

Risk for Myopathy With Statin Therapy in High-Risk Patients
Ballantyne et al.
Arch Intern Med 2003;163:553-564.
ABSTRACT | FULL TEXT  

Direct vascular and cardioprotective effects of rosuvastatin, a new HMG-CoA reductase inhibitor
Jones et al.
J Am Coll Cardiol 2002;40:1172-1178.
ABSTRACT | FULL TEXT  

Safety and Tolerability of Pravastatin in Long-Term Clinical Trials: Prospective Pravastatin Pooling (PPP) Project
Pfeffer et al.
Circulation 2002;105:2341-2346.
ABSTRACT | FULL TEXT  

Risk of Cataract in Patients Treated With Statins
Schlienger et al.
Arch Intern Med 2001;161:2021-2026.
ABSTRACT | FULL TEXT  

Risk factors for a major coronary event after myocardial infarction in the Scandinavian Simvastatin Survival Study (4S). Impact of predicted risk on the benefit of cholesterol-lowering treatment
Wilhelmsen et al.
Eur Heart J 2001;22:1119-1127.
ABSTRACT  

Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease
Lefer et al.
Cardiovasc Res 2001;49:281-287.
FULL TEXT  

Cholesterol reduction and non-illness mortality: meta-analysis of randomised clinical trials
Muldoon et al.
BMJ 2001;322:11-15.
ABSTRACT | FULL TEXT  

Statin Drugs and the Risk of Fracture
El-Sohemy et al.
JAMA 2000;284:1921-1922.
FULL TEXT  

Use of Simvastatin Treatment in Patients With Combined Hyperlipidemia in Clinical Practice
Vicari et al.
Arch Fam Med 2000;9:898-905.
ABSTRACT | FULL TEXT  

3 Year simvastatin treatment and lens nuclear back scattering
Qian et al.
Br. J. Ophthalmol. 2000;84:512-516.
ABSTRACT | FULL TEXT  

Case 12-2000- A 60-Year-Old Man with Persistent Gynecomastia after Excision of a Pituitary Adenoma
Hayes and Eichhorn
NEJM 2000;342:1196-1204.
FULL TEXT  

The Insulin-Like Growth Factor Axis : A Review of Atherosclerosis and Restenosis
Bayes-Genis et al.
Circ. Res. 2000;86:125-130.
ABSTRACT | FULL TEXT  

Drug interactions and the statins
Herman
CMAJ 1999;161:1281-1286.
ABSTRACT | FULL TEXT  

Clinical Outcomes in Statin Treatment Trials: A Meta-analysis
Ross et al.
Arch Intern Med 1999;159:1793-1802.
ABSTRACT | FULL TEXT  

Alternatives to the Use of Estrogen in Postmenopausal Women
Pinkerton and Santen
Endocr. Rev. 1999;20:308-320.
ABSTRACT | FULL TEXT  

The use of statins following AMI
BURGESS; and KHONG
Postgrad. Med. J. 1999;75:382a-382.
FULL TEXT  

Lipoprotein Changes and Reduction in the Incidence of Major Coronary Heart Disease Events in the Scandinavian Simvastatin Survival Study (4S)
Pedersen et al.
Circulation 1998;97:1453-1460.
ABSTRACT | FULL TEXT  

An Overview of the Clinical Safety Profile of Atorvastatin (Lipitor), a New HMG-CoA Reductase Inhibitor
Black et al.
Arch Intern Med 1998;158:577-584.
ABSTRACT | FULL TEXT  

Cholesterol-Lowering Therapy in Women and Elderly Patients With Myocardial Infarction or Angina Pectoris : Findings From the Scandinavian Simvastatin Survival Study (4S)
Miettinen et al.
Circulation 1997;96:4211-4218.
ABSTRACT | FULL TEXT  

Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo
Fassbender et al.
Proc. Natl. Acad. Sci. USA 2001;98:5856-5861.
ABSTRACT | FULL TEXT